Abstract-Bubble-seeded histotripsy (BSH) is a newly developed ultrasound-based mechanical fractionation technique using locally injected phase change nanodroplets (PCNDs) as sensitizers. The PCNDs are a kind of microbubble precursor compressed into submicron-size in droplets form, which were designed for local administration and will expand into microbubbles under ultrasound exposure. Previously, we reported that a combination of PCNDs injection and pulsed high-intensity focused ultrasound (pHIFU) with an acoustic intensity as low as about 3 kW/cm 2 at 1.1 MHz, which is similar to the acoustic intensity of currently available HIFU coagulation therapy, was enough to induce tissue fractionation after significant antitumor effects in an in vivo study. Toward therapeutic application of BSH to deep-seated tissues such as the pancreas, the transluminal approach, using endoscopic ultrasound was thought to be ideal. Therefore, for a preliminary examination, we developed a new transducer with a small aperture (20-× 20-mm square) and long focal length (35 mm), operating at 2.1 MHz that could be attached to an EUS-mimicking probe. With the newly developed transducer and locally injected PCNDs, predictable tissue mechanical fractionation was observed in both ex vivo and in vivo studies at acoustic intensities that were too low to induce any significant bioeffects (around 4 kW/cm 2 ) without using PCNDs. For in situ monitoring of the treatment site during a procedure, the degree of attenuation of microbubble motions after exposing the microbubbles to pHIFU was monitored, using ultrafast echographic imaging. Microbubble movements were observed to be largest at 25-30 s after pHIFU exposure. On the contrary, after 40 s, the movement of microbubbles decreased to the same level as at the start of the procedure, suggesting that an overdose of pHIFU exposure causes coagulation attributable to the thermal effect caused by absorption of the energy. Those results were promising for expanding the application of BSH for a transluminal approach, using a small transducer under real-time monitoring.
INTRODUCTION
Histotripsy (Hall et al. 2009; Lake et al. 2008; Roberts et al. 2006; Xu et al. 2004 ) has made the mechanical effects of ultrasound a main part of research for therapeutic application and developed it into an ultrasonic minimally invasive therapy system. Histotripsy is a controllable mechanical tissue fractionation induced by repetitive short ultrasound pulses at extremely high intensities, which was originally reported by a research group at the University of Michigan (Xu et al. 2004) . A clinical trial for the treatment of benign prostate hyperplasia (Roberts 2014) is now ongoing, and research on other applications, such as transcranial clot liquefaction (Zhang et al. 2015) , prostate cancer and renal stones, are being carried out intensively (Roberts 2014). Before the development of histotripsy, ultrasound bioeffects used for therapeutic applications had mainly been thermal effects that raise the targets' temperatures enough to induce tissue coagulation (Hill and ter Haar 1995) . Therapies using such thermal effects are referred to as high-intensity focus ultrasound (HIFU) therapies (Aus 2006) , and now they are clinically available for both benign (Ebert et al. 1995; Hynynen et al. 2001 ) and malignant diseases (Hill and ter Haar 1995; Hou et al. 2009; Khokhlova and Hwang 2011) .
Histotripsy has many potential advantages over HIFU therapy as follows: (i) It is supposed to be less dependent on the vascularity of the tissues and more suitable to treat sites adjacent to large vessels. Applying HIFU therapy to such sites may result in insufficient therapeutic effects attributable to a mechanism referred to as the heat sink effect (Jiang et al. 2013 ). (ii) The therapeutic process of histotripsy can easily be monitored as the acoustic images change during the procedure (Vlaisavljevich et al. 2013) . In HIFU therapy, it is difficult to monitor the temperature change caused in conjunction with the change of acoustic parameters because acoustic parameters such as sound speed and attenuation coefficient have different temperature dependencies (Ghoshal et al. 2011) and are difficult to measure separately. (iii) Mechanical tissue fractionation induced by histotripsy allows anticancer drugs to penetrate cancer cells, while the thermal effects of HIFU cause tissue coagulation followed by fibrosis, which makes it difficult for anticancer drugs to reach the cancer cells.
Although histotripsy has much potential as described earlier in this report, it needs a very high amplitude and negative peak pressure of more than 20 MPa (Hall et al. 2009 ), which roughly corresponds to 40 kW/cm 2 (Xu et al. 2013) . Therefore, transducers with large aperture sizes are necessary, which makes it difficult to apply histotripsy to a lesion by an intercostal approach, and the treatment of deep-seated regions is thought to be difficult because of the attenuation of acoustic energy inside the body.
Therefore, considering the histotripsy characteristics discussed earlier in this report, we previously developed a therapeutic system referred to as bubble-seeded histotripsy (BSH) that combines pulsed ultrasound and a locally injected sensitizer to induce mechanical fractionation that is similar to histotripsy with a reduced acoustic amplitude that is as low as that of HIFU therapy (several kW/cm 2 intensity), utilizing conventional HIFU exposure systems. For BSH, we use a special contrast agent as a sensitizer that changes its phase from liquid to vapor (microbubbles), referred to as phase change nanodroplets (PCNDs) (Asami et al. 2010) . Moreover, we aimed to develop a new system for cancer treatment, using direct low-dose antitumor agent administration (Ashida et al. 2015; Kawabata et al. 2013 Kawabata et al. , 2014 . No other studies on cancer treatments, using tissue fractionation at such a low intensity with the aid of PCNDs seem to have succeeded, although the effects of nanodroplets on histotripsy have been investigated with tissue-mimicking phantoms for drug delivery purposes (Vlaisavljevich et al. 2015 (Vlaisavljevich et al. , 2016 .
Regarding the transluminal approach, several studies report on HIFU therapy using the endoscopic approach for the liver or pancreas. Hwang's group successfully ablated porcine liver and pancreatic tissues with an endoscopic ultrasound (EUS)-guided HIFU system (Li et al. 2015) . However, histotripsy-like mechanical effects does not seem to occur in their situation. Therefore, it is worthwhile to develop therapeutic systems for the transluminal approach, utilizing mechanical effects, given the advantages of the mechanical effects as described earlier in this report.
In this report, based on the previous successful feasibility test of BSH, we further discuss the feasibility of BSH being applied in the transluminal approach. A transluminal approach would be suitable for treating deepseated tissues such as the pancreas, but it is challenging to develop a system because a small aperture and long focal length is essential, and the system needs to be very small. The conceptual differences between transducers for conventional and transluminal approaches are presented in Figure 1 . In addition to showing a transducer for conventional extracorporeal approach, Figure 1 describes a transducer for micro histotripsy (Woodacre et al. 2016) , which aims to treat very small surface regions.
We also developed a real-time BSH monitoring method during the treatment. Previously we used the strain ratio to evaluate the stiffness of the tissue after the procedure. However, it is difficult to monitor the strain ratio in real time because it cannot be measured during the pHIFU exposure. Therefore, in this study, we utilized realtime movement evaluation of microbubbles derived from PCNDs, using ultrafast imaging during the procedure.
MATERIALS AND METHODS

Chemicals
Perfluoro-n-pentane (PFP), perfluoro-n-hexane (PFH) and chloroform were purchased from Wako Pure Chemical Industries (Osaka, Japan) and used without further purification. Dipalmitoyl-phosphatidylcholine (DPPC), dipalmitoyl-phosphatidic acid (DPPA) and PEGylated dipalmitoyl-phosphatidylethanolamine (PEG-DPPE) were purchased from NOF Corporation (Tokyo, Japan). 
